Deals

Roth Capital Places AEterna Zentaris CMPO

By |

AEterna Zentaris (AEZS) announced that it has raised $16.5 million in a CMPO/Overnight transaction. The common stock was sold at $2.50 per share, an approximate 21% discount to the market price ($3.15) of AEZS at deal announcement. Roth Capital Partners acted as the exclusive agent on the transaction. Placement agent counsels were Gowling Lafleur Henderson and Lowenstein Sandler, and issuer counsels were Norton Rose Canada, along with Ropes & Gray. The transaction is expected to close by Oct.

Markets
Biotech

IPOs Looking Good to Biotechs

By |

Share prices of Kythera Biopharmaceuticals (KYTH) and Intercept Pharmaceuticals(ICPT) popped significantly Thursday following their initial public offerings, indicating an appetite for fresh biotech issues. Calabasas, Calif.-based Kythera, which sold 4.4 million shares for $16 each to raise $70.4 million, opened at $18.49 a share and ended the day at $19.79 a share. New York-based Intercept sold 5 million shares at $15 each to raise $75 million. It opened at $19.40 a share and closed its first day at $19.40 a share. In both cases, the issuers upsized the number of shares offered and priced at the high end of their respective ranges.

Deals

Regulus Therapeutics Dual Tracks PIPE, IPO

By |

MicroRNA therapeutics developer Regulus Therapeutics (RGLS) announced that it has raised $25 million in a Common Stock transaction with investor AstraZeneca AB. The common stock was sold at $4.00 per share, an approximate 5% discount to the market price ($4.20) of RGLS at deal announcement.. The transaction closed on Oct. 10, 2012. This Placement was conducted concurrently with the Company's Initial Public Offering.

Deals

MLV & Co. Investing in Geron ATM

By |

Geron Corp. (GERN) announced that it has secured up to $50 million in an ATM (At the Market) transaction with MLV & Co. The company is developing several new

oncology treatments. The purchase price is the prevailing market price at the time of the Draw Down Notice. Placement Agent counsel was LeClairRyan, and issuer counsel was Cooley.